Frank ZhangMS, PhD
For the past 16 years, Dr. Zhang has been the Chairman and Chief Executive Officer of GenScript Inc., the world’s largest gene synthesis corporation. In 2014, Dr. Zhang founded Legend Biotech under GenScript Inc., expanding the corporation’s business goal to research, manufacture, and commercialize a broad range of immunotherapy treatments. In 2018, Legend Biotech became the first Chinese CAR-T company to receive Investigational New Drug approval in both China and the United States. That same year, Dr. Zhang was awarded Person of the Year at the China Healthcare Summit in recognition of his contribution to and significant impact on the healthcare field.
Before founding GenScript Inc., Dr. Zhang worked as a Principal Scientist at Schering-Plough from 1995 to 2002 where he received its Presidential Award. Dr. Zhang received his Ph.D. in biochemistry from Duke University in Durham, North Carolina, USA; and his Master’s degree from Nanjing University, China. Dr. Zhang has authored more than 20 articles published in peer-reviewed journals and is the owner of 9 scientific patents.